## Introduction
The transition from the Medical Device Directive (MDD) to the **Medical Device Regulation (EU MDR 2017/745)** represents the biggest shift in European medtech history. For orthopedic distributors, “business as usual” is over. Adapting to these strict standards is now a survival requirement.
## Key Changes Under MDR
The MDR has significantly raised the bar for safety and clinical performance:
* **Stricter Clinical Evidence:** Implants now require more robust, long-term clinical data to maintain their CE mark.
* **UDI and Traceability:** Every screw and plate must have a Unique Device Identifier (UDI) for total transparency in the supply chain.
* **Post-Market Surveillance (PMS):** Manufacturers and distributors must actively collect and report data on how the device performs after it is implanted.
## The Impact on Orthopedic Implants
Since most orthopedic implants are **Class IIb or Class III**, they fall under the highest level of scrutiny. Many legacy products from smaller manufacturers may disappear from the market because they cannot meet the new clinical data requirements.
## How Ortholyx Supports Distributors
Ortholyx has invested heavily in MDR transition. We provide our partners with:
1. Full technical dossiers compliant with 2017/745.
2. Robust PMS systems to track clinical success.
3. Clear UDI labeling for easy inventory management.
## Conclusion
While the EU MDR is a hurdle, it is also a filter that separates high-quality manufacturers from the rest. By partnering with MDR-ready suppliers like Ortholyx, distributors can secure their position in the European market for the next decade.